HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bestehorn, H.-P. Articles by Roskamm, H. Search for Related Content PubMed PubMed Citation Articles by Bestehorn, H.-P. Articles by Roskamm, H.

Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention

The randomized, double-blind, placebo-controlled, multicenter verapamil slow-release for prevention of cardiovascular events after angioplasty (VESPA) trial

Hans-Peter Bestehorn, MD^*,*, Franz-Josef Neumann, MD^*, Heinz Joachim Büttner, MD^*, Peter Betz, MD, PhD^*, Peter Stürzenhofecker, MD, Eberhard von Hodenberg, MD, Antoine Verdun, MD, Laszlo Levai, MD, Jean Pierre Monassier, MD^|| and Helmut Roskamm, MD^*

^* Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
Herz-und Gefäßklinik Bad Neustadt, Bad Neustadt, Germany
Herz-Zentrum Lahr, Lahr, Germany
Clinic St. Joseph Colmar, Colmar, France
^|| Hospital Emil Müller, Mulhouse, France

View larger version (30K): [in a new window]   Figure 1 Trial profile. PCI = percutaneous catheter intervention.

View larger version (12K): [in a new window]   Figure 2 Cumulative distribution curves for percent diameter stenosis at follow-up in the two treatment groups.